10:37 AM EST, 03/06/2025 (MT Newswires) -- Scienture ( SCNX ) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.

Financial details weren't disclosed.

Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture ( SCNX ) will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.

Shares of Scienture ( SCNX ) jumped more than 31% in recent Thursday trading.

Price: 2.83, Change: +0.62, Percent Change: +28.05